SAN FRANCISCO, Nov. 4 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. , a leading RNAi therapeutics company, announced today that J. Michael French, Sirna’s Senior Vice President of Corporate Development, is scheduled to present at BIO-Europe 2005 on Wednesday, November 9, 2005 at 12:45 p.m. CEST (6:45 am EST; 4:45 am MST; 3:45 am PST) at the International Congress Center in Dresden, Germany.
The presentation will not be webcast. For more information on this conference, please log onto http://www.bio.org.
About Sirna Therapeutics
Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington’s disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., has been shown to be safe and well tolerated with a trend toward visual acuity improvement and demonstrated biological activity. Sirna has a leading intellectual property portfolio in RNAi with 45 issued patents and over 250 pending applications worldwide. More information on Sirna Therapeutics is available on the Company’s web site at www.sirna.com.
Contacts: Rebecca Galler Robison, Senior Director, Corporate Strategy Sirna Therapeutics, Inc., +1-303-449-6500 Francesca DeMartino (investors) or Jason Rando (media), both of The Ruth Group, +1-646-536-7024 / 7025
Sirna Therapeutics, Inc.
CONTACT: Rebecca Galler Robison, Senior Director, Corporate Strategy ofSirna Therapeutics, Inc., +1-303-449-6500; or Investors, FrancescaDeMartino, +1-646-536-7024, or Media, Jason Rando, +1-646-536-7025, both ofThe Ruth Group, for Sirna Therapeutics, Inc.
Web site: http://www.bio.org/http://www.sirna.com/
